Bio-Path Holdings has announced promising results from preclinical trials of its compound, BP1001-A, aimed at treating obesity, which also revealed an improvement in insulin sensitivity. These findings position BP1001-A as a viable treatment option for obesity and associated metabolic disorders in individuals with Type 2 diabetes. The compound works by suppressing the expression of the growth factor receptor-bound protein 2, thereby enhancing insulin sensitivity and aiding in the reduction of blood glucose levels in patients with Type 2 diabetes.
The company has begun conducting animal studies to validate the efficacy of BP1001-A for treating obesity and metabolic diseases related to Type 2 diabetes. Should these studies prove successful, Bio-Path intends to launch its first human clinical trial, Phase 1, by 2025.
In response to these developments, Bio-Path’s shares have surged by 65% during pre-market trading on Thursday.
The material has been provided by InstaForex Company - www.instaforex.com
The company has begun conducting animal studies to validate the efficacy of BP1001-A for treating obesity and metabolic diseases related to Type 2 diabetes. Should these studies prove successful, Bio-Path intends to launch its first human clinical trial, Phase 1, by 2025.
In response to these developments, Bio-Path’s shares have surged by 65% during pre-market trading on Thursday.
The material has been provided by InstaForex Company - www.instaforex.com